San Diego oph­thalmic biotech up­start rais­es $28M on al­ter­na­tive to corneal trans­plant

Texas VC Bios Part­ners has found a new ear­ly-stage play to love out of San Diego, lead­ing a $28 mil­lion Se­ries A to help Tre­foil Ther­a­peu­tics make the leap to the clin­ic.

Stel­la Robert­son, who head­ed R&D at No­var­tis’ eye care unit Al­con be­fore co-found­ing Bios Part­ners, is par­tic­u­lar­ly ex­cit­ed about this one. With a tech plat­form that en­gi­neers fi­brob­last growth fac­tor-1 pro­tein (FGF-1), Tre­foil is out to tack­le se­ri­ous corneal en­dothe­lial dis­eases and ep­ithe­lial dis­or­ders by prompt­ing the en­dothe­lial cells to flour­ish and mi­grate. Ul­ti­mate­ly — if the pre­clin­i­cal da­ta hold up — the goal is to en­hance heal­ing and re­verse vi­sion loss.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER